Cynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients with Parkinson’s Disease
June 30, 2016 06:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, June 30, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to...
Cynapsus Therapeutics Announces Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders
June 21, 2016 06:30 ET
|
Cynapsus Therapeutics Inc.
-- Presentations include results from physician, patient and caregiver primary research, positive preclinical toxicology results and physician OFF episode treatment practices -- TORONTO, June 21,...
Cynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual Meeting
May 30, 2016 02:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, May 30, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics, Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to...
Cynapsus Therapeutics Appoints Frederick Driscoll to Its Board of Directors
May 20, 2016 06:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, May 20, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus” or the “Company”) (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (“CNS”) pharmaceutical company...
Cynapsus Therapeutics Reports First Quarter 2016 Financial Results and Recent Developments
May 11, 2016 16:30 ET
|
Cynapsus Therapeutics Inc.
TORONTO, May 11, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a...
Cynapsus Therapeutics Announces Results of AGM
May 11, 2016 16:15 ET
|
Cynapsus Therapeutics Inc.
TORONTO, May 11, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) (“Cynapsus” or the “Company”), a specialty central nervous system pharmaceutical company developing and...
Cynapsus Therapeutics to Present at Several Upcoming Investor Conferences
April 28, 2016 06:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, April 28, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a...
Cynapsus Therapeutics Announces Data Presentations at the American Academy of Neurology Annual Meeting
April 15, 2016 06:00 ET
|
Cynapsus Therapeutics Inc.
TORONTO, April 15, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (“CNS”) pharmaceutical company developing and preparing to...
Cynapsus Therapeutics and MonoSol Rx Announce Global IP Licensing Agreement
TORONTO and WARREN, N.J., April 04, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (“Cynapsus” or the “Company”) (NASDAQ:CYNA) (TSX:CTH), and MonoSol Rx LLC (“MonoSol Rx”) today announced that...
Cynapsus Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended 2015
March 09, 2016 16:15 ET
|
Cynapsus Therapeutics Inc.
TORONTO, March 09, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a...